Welcome to our dedicated page for United Therapeutics SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share on March 6, 2026. She then sold 9,500 shares in multiple open-market transactions at prices reported between $471.96 and $484.27 per share.
The filing notes these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which runs until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026. Following the sales, she holds 130 shares directly and additional indirect holdings through her spouse and family trusts.
United Therapeutics Corporation authorized a new stock repurchase program of up to $2.0 billion of common stock to be executed before March 9, 2027. To launch the program, the company entered into two accelerated share repurchase agreements with Citi totaling $1.5 billion, split between a $750 million uncollared ASR and a $750 million collared ASR.
The company will make an upfront payment of $1.5 billion on or around March 11, 2026 and expects initial delivery of approximately 992,120 shares under the uncollared ASR and approximately 708,657 shares under the collared ASR. Final shares repurchased will depend on the average daily volume-weighted average price over each ASR term, with the uncollared ASR scheduled to end in the second quarter of 2026 and the collared ASR in the third quarter of 2026. An additional $500 million remains authorized for future repurchases over the next year at the company’s discretion.
UNITED THERAPEUTICS Corp director Judy D. Olian sold common stock in a planned transaction. On March 6, 2026, she completed an open-market sale of 200 shares of common stock at a price of $510 per share, leaving her with 4,645 shares held directly.
According to a footnote, this sale was made under a pre-arranged Rule 10b5-1 trading plan that she entered into on November 24, 2025. Such plans are designed to allow insiders to systematically sell shares over time according to predetermined instructions.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares on March 5, 2026, converting derivative securities into common stock at a reported exercise price of $146.03 per share.
On the same date, she sold a total of 9,500 common shares in a series of open-market transactions, with reported weighted-average prices ranging from $479.8871 to $487.9813, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she directly held 130 common shares, in addition to indirect holdings reported as 166 shares by spouse and 324,518, 258,117, 45,596 and 10,962 shares held by various family trusts.
Judy Olian reported the sale of 200 common shares. The Form 144 shows 200 restricted shares granted 06/26/2021 and sold on 03/02/2026 for $101,910.00. The filer is listed as Morgan Stanley Smith Barney LLC.
UNITED THERAPEUTICS Corp executive Paul A. Mahon, EVP & General Counsel, reported exercising stock options and selling resulting shares. On March 5, 2026, he exercised 8,300 stock options at a reported price of $0.0000 per option, receiving 8,300 shares of common stock at a reported price of $146.0300 per share.
The filing shows multiple open-market sales totaling 8,300 shares of common stock on the same date at reported weighted average prices between about $479.4271 and $487.6520. A footnote states these option exercises and related sales were made under a pre-arranged 10b5-1 trading plan entered into on August 11, 2025. After these transactions, Mahon directly held 36,844 shares of common stock and 33,500 stock options as of March 5, 2026, including 63 shares acquired on March 4, 2026 under the United Therapeutics Employee Stock Purchase Plan.
United Therapeutics Corp Chairperson and CEO Martine A. Rothblatt reported an insider transaction involving stock options and common shares. On March 4, 2026, she exercised 9,500 stock options (labeled as Stock Options) at a reported exercise price of $0.0000 per share, leaving her with 211,500 stock options held directly following the exercise.
The same day, she executed a series of open-market sales totaling 19,000 shares of Common Stock, with reported per‑share prices including $486.4229 and up to $497.0500. After these sales, she held 130 shares of Common Stock directly. Additional indirect Common Stock holdings are reported as 166 shares held by spouse and 324,518, 258,117, 45,596, and 10,962 shares held by various family trusts. A footnote states that the option exercise and related share sales were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025, which will continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
United Therapeutics Corp director Ray Kurzweil reported a set of transactions involving company stock. On March 4, 2026, he exercised a stock option for 4,910 shares, which resulted in acquiring 4,910 shares of common stock at a stated price per share of 101.8000. On the same date, he then sold 4,910 shares of common stock at a reported price per share of 489.0200. After these transactions, his directly owned common stock holdings were 12,670 shares.
UNITED THERAPEUTICS Corp director Tommy G Thompson reported multiple transactions on March 4, 2026. He exercised a stock option for 2,000 options, labeled as an exercise or conversion of a derivative security, resulting in 2,000 options held afterward.
On the same date, he acquired 2,000 shares of common stock through this option exercise at a price of $101.8000 per share, bringing his direct common stock holdings to 10,480 shares. He then executed an open-market sale of 2,000 common shares at a weighted average price of $489.4197 per share, leaving 8,480 directly held shares.
A footnote states that his direct holdings include 880 additional common shares to be issued on or about July 8, 2026 from previously vested RSUs for which receipt was deferred. Indirectly, 8,200 common shares are held by a trust and 5,800 common shares are held through a Family LLC associated with him.
UNITED THERAPEUTICS Corp director Christopher Causey exercised stock options for 20 shares on March 4, 2026, converting them into common stock at a price of $119.76 per share. He then sold 20 common shares in an open-market transaction at a weighted average price of $490.1685 per share.
The option exercise and subsequent sale were carried out under a pre-arranged Rule 10b5-1 trading plan that Causey entered into on September 30, 2025. The sale occurred in multiple trades, with individual prices ranging from $490.12 to $490.21, and left him with 4,190 common shares held directly.